This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. ICD-10 code | E83.3 | Special Copayment Reduction: V189 |
| B. Synonyms | Familial hypophosphatemia, vitamin D-resistant osteomalacia, vitamin D-resistant rickets, X-linked hypophosphatemic rickets (XLH), disorders of phosphorus metabolism and phosphatases (general category), PHEX-related hypophosphatemia, FGF23-mediated hypophosphatemia |
| C. Adult onset | First onset in adulthood unlikely — presents with growth delay and rickets in childhood, but is sometimes first diagnosed in adulthood with osteomalacia, dental abscesses or enthesopathy |
| 1. History | First description of vitamin D-resistant rickets in the 1930s; through discovery of the PHEX gene and approval of burosumab |
| 2. Causes | PHEX gene mutation → excess FGF23 secretion → reduced renal phosphate reabsorption and suppressed calcitriol synthesis |
| 3. Genetics | X-linked dominant (XLD); PHEX gene Xp22.11; hemizygous males more severe |
| 4. General epidemiology | Prevalence about 1/20,000; the most common form of hereditary rickets |
| 5. Pathophysiology | Excess FGF23 → NaPi-IIa/IIc downregulation → renal phosphate wasting → hypophosphatemia → impaired bone mineralization |
| 6. Symptoms | Rachitic lower limb deformities, growth delay, dental abscesses, myalgia, osteomalacia and enthesopathy in adulthood |
| 7. Signs | Low serum phosphorus, reduced tubular phosphate reabsorption (low TmP/GFR), elevated ALP, inappropriately normal calcitriol |
| 8. Screening | Serum phosphorus, urinary phosphate, family history; neonatal screening not established |
| 9. Diagnosis | Hypophosphatemia + low TmP/GFR + elevated plasma FGF23 + PHEX gene variant |
| 10. Treatment | Burosumab (anti-FGF23 monoclonal antibody); conventional combination therapy with phosphate + active vitamin D |
| 11. Prognosis | Growth delay and bone deformities may persist, but dramatic improvement with burosumab; management of enthesopathy and kidney stones needed in adulthood |
| 12. Prevention | Minimize complications through genetic counseling, family screening and early treatment |
| 13. References | 10 key references |
Vitamin D-resistant rickets became known in the 1930s when Albright and colleagues first described cases of rickets that did not respond to standard therapeutic doses of vitamin D. Later, in 1958, Winters and colleagues demonstrated through pedigree analysis that the disease is transmitted by an X-linked dominant mode of inheritance, and the name "X-linked Hypophosphatemia (XLH)" became established. At the time it was understood simply as reduced renal phosphate reabsorption, but its molecular mechanism remained unclear for decades.
In 1995, the HYP Consortium discovered the PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) gene and mapped it to Xp22.11. PHEX is a gene of the zinc metalloendopeptidase family, but subsequent studies showed that it is indirectly involved in the regulation of FGF23 rather than actually cleaving a substrate directly.
In the early 2000s, fibroblast growth factor 23 (FGF23) was identified as a key factor regulating phosphate metabolism, and FGF23 was confirmed to be markedly elevated in patients with XLH. This fundamentally changed the understanding of the pathophysiology of XLH. In 2018, the anti-FGF23 monoclonal antibody burosumab (brand name Crysvita®) received FDA and EMA approval for pediatric XLH, and its indication was later extended to adult XLH. This is the most groundbreaking advance in the history of XLH treatment, greatly reducing the limitations of conventional oral phosphate + active vitamin D therapy (adverse effects such as nephrocalcinosis and hyperparathyroidism).
The direct cause of XLH is a loss-of-function mutation of the PHEX gene. The PHEX gene encodes a zinc-dependent metalloendopeptidase expressed mainly in bone (osteoblasts, osteocytes) and teeth (odontoblasts). How loss of PHEX function leads to excess FGF23 production has not yet been fully elucidated, but it has been proposed that PHEX is directly or indirectly involved in the extracellular degradation of the FGF23 protein, or that a pathway mediated by ASARM (acidic serine- and aspartate-rich motif) peptides in the bone matrix is involved.
FGF23 downregulates the sodium-phosphate cotransporters (NaPi-IIa, NaPi-IIc) of the renal proximal tubule to reduce phosphate reabsorption, and at the same time suppresses 1α-hydroxylase (CYP27B1) and activates 24-hydroxylase (CYP24A1) to inhibit the synthesis of circulating active vitamin D (calcitriol, 1,25(OH)₂D₃). Through this dual effect, intestinal phosphate absorption also decreases. As a result, hypophosphatemia in XLH is sustained through both renal and intestinal routes.
When hypophosphatemia persists, phosphate ions (HPO₄²⁻) needed for mineralization of the bone extracellular matrix become deficient, and hydroxyapatite crystal formation is inhibited. Local extracellular pyrophosphate (PPi) levels in osteoblasts are also known to be elevated in XLH, contributing to the inhibition of bone mineralization.
Rarely, mutations in other genes produce phenotypes similar to XLH. These include autosomal dominant hypophosphatemic rickets (ADHR) due to gain-of-function variants of FGF23 itself, autosomal recessive hypophosphatemic rickets (ARHR2) due to ENPP1 variants, and ARHR1 due to DMP1 variants, all of which share elevated FGF23 as a common mechanism.
XLH follows an X-linked dominant (XLD) mode of inheritance. The causative gene, PHEX, is located on the short arm of the X chromosome (Xp22.11) and consists of 22 exons. Due to the nature of this mode of inheritance, both males (hemizygous) and females (heterozygous) are affected, and males generally show a more severe phenotype.
More than 800 pathogenic variants of the PHEX gene have now been reported, with a diverse distribution of missense, nonsense and splicing variants and small/large deletions. Specific founder mutations have been reported in some ethnic groups. Genotype-phenotype correlation is unclear, and phenotypic variation is large even within the same family. In particular, heterozygous females may be asymptomatic or show only mild hypophosphatemia, while others show overt rickets.
About 20–30% of mutations are estimated to arise de novo. Therefore, XLH should not be ruled out even in children with rickets and no family history. Genetic testing is useful not only for confirming the diagnosis but also for identifying carriers (heterozygous females) regardless of sex. Because the gene is on the X chromosome, transmission from father to son does not occur (no male-to-male transmission), and with father-to-daughter transmission the daughter is always affected.
Recent large-scale whole-genome analysis studies have further expanded the spectrum of genetic variants in XLH, and genotype-phenotype studies are actively under way. There are domestic reports on the PHEX variant spectrum in Korean patients, but they are limited in scale.
XLH is the most common form of hereditary hypophosphatemic rickets, with a worldwide prevalence estimated at about 1/20,000 births. Prevalence differences between races and regions are not large, but founder effects appear in some populations. There is no difference in prevalence by sex (both males and females are affected because of XLD inheritance), but clinical severity tends to be greater in males.
In Korea, studies based on health insurance data are limited, but based on the number of patients registered for Special Copayment Reduction, the number is estimated at several hundred. As diagnostic awareness increases, the number of registered patients is gradually increasing. Since the introduction of burosumab in 2018, greater willingness of medical institutions to confirm XLH has also contributed to the increase in registrations.
Although XLH is apparently the most common hereditary rickets, there are still patients who are confused with vitamin D deficiency rickets and go years without treatment, or who see no effect from vitamin D treatment alone. The average resulting diagnostic delay is reported in international studies to be 4–6 years.
The core pathophysiology of XLH is chronic excess activation of FGF23. Under normal conditions, FGF23 is secreted from bone and travels to the renal proximal tubule, where it binds to a complex of the FGF receptor (FGFR1c) and the coreceptor Klotho to finely regulate phosphate reabsorption. In XLH, loss of PHEX function decreases degradation or increases production of FGF23, so circulating FGF23 concentrations remain persistently elevated.
Elevated FGF23 exerts two key effects in the renal proximal tubule. First, it suppresses the expression and membrane insertion of the sodium-phosphate cotransporters NaPi-IIa (SLC34A1) and NaPi-IIc (SLC34A3), reducing phosphate reabsorption. The indicator reflecting this is a decrease in the ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP/GFR). Second, it suppresses CYP27B1 (1α-hydroxylase) and activates CYP24A1 (24-hydroxylase), inhibiting the synthesis of active vitamin D (1,25(OH)₂D₃, calcitriol). Low calcitriol leads to reduced intestinal absorption of calcium and phosphate.
The resulting hypophosphatemia disrupts the differentiation and hypertrophy of growth plate chondrocytes and lowers the phosphate ion concentration needed for mineralization of the bone extracellular matrix, causing rachitic widening of the growth plates and osteomalacia. Looser zones (pseudofractures) develop in the cortical bone of long bones, and defects arise in the predentin of the teeth, causing bacterial invasion and spontaneous dental abscesses. In adulthood, abnormal ossification at tendon and ligament insertions (enthesopathy) progresses, causing pain, restricted mobility, spinal canal stenosis and so on.
Childhood symptoms: XLH is usually first noticed as lower limb deformity around the time a child begins to walk (12–18 months of age). Genu varum (bowlegs) is the most common, and genu valgum may also occur. Growth delay and short stature are present, and without treatment final height is markedly reduced. As a craniofacial abnormality, craniosynostosis rarely occurs. Dental abscesses are very characteristic of XLH, and dental abscesses arising spontaneously without caries are often a diagnostic clue to XLH. Myalgia, muscle weakness and pain on walking are also common.
Adult symptoms: If not diagnosed in childhood, the disease may first present in adulthood. Fatigue, lower limb pain and difficulty walking are the main symptoms. Abnormal ossification at tendon and ligament insertions (enthesopathy) causes pain and stiffness in the spine, hips, ankles and elsewhere, and as it progresses leads to gait impairment and spinal canal stenosis. Osteomalacic pseudofractures (Looser zones) occur in the femur and other long bones. In adult women, it is sometimes mistaken for osteoporosis or postmenopausal bone loss.
Hearing loss (sensorineural hearing loss) has been reported in some patients and may be related to craniosynostosis. Kidney stones and nephrocalcinosis can occur as adverse effects of conventional treatment (oral phosphate + active vitamin D).
Physical signs: Angular lower limb deformities (genu varum or genu valgum), reduced height (especially short lower limbs), gait abnormality (waddle gait) and craniofacial abnormalities are observed. Dental examination may show traces of abscesses or early prosthetic restorations.
Biochemical signs: Low serum phosphorus (Pi) (adults <2.5 mg/dL, children <3.5–4.0 mg/dL) is the key finding. Serum calcium is normal. The tubular maximum reabsorption of phosphate/GFR (TmP/GFR) is reduced, demonstrating renal phosphate wasting. Serum alkaline phosphatase (ALP) is usually elevated (osteomalacia/rickets response). Serum FGF23 is elevated or inappropriately within the normal range (a normal value in the setting of hypophosphatemia is regarded as inappropriately elevated). Serum PTH is normal or mildly elevated. Serum calcitriol (1,25(OH)₂D₃) is inappropriately low or within the normal range relative to the hypophosphatemia.
Imaging signs: Lower limb X-rays show rachitic widening of the growth plates (metaphyseal cupping/fraying), bowing and shortening of long bones, and Looser zones. In adults, CT and MRI of the lumbar spine and sacrum may show abnormal ossification at ligament insertions and spinal canal stenosis. Nephrocalcinosis seen on renal ultrasound suggests an adverse effect of conventional treatment.
National newborn screening for XLH has not been established at present. The screening approach used when XLH is clinically suspected is as follows.
Serum phosphorus measurement: This is the first screening test. In children with XLH, serum phosphorus is persistently below the lower limit of normal for age. Persistence of hypophosphatemia is confirmed by repeated measurements rather than a single measurement. Because postprandial values may be lower than fasting values, measurements are made under consistent conditions.
Urinary phosphate and TmP/GFR: To demonstrate renal phosphate wasting, the phosphate/creatinine ratio is measured in a spot urine or 24-hour urine and TmP/GFR is calculated. A low TmP/GFR strongly suggests XLH.
Family history screening: Measurement of serum phosphorus and ALP is recommended in first-degree relatives of patients with XLH. When the mother has confirmed XLH, testing is needed in both sons and daughters. Asymptomatic female carriers may also have low serum phosphorus.
In children with gait abnormalities: In children with angular lower limb deformities, serum calcium, phosphorus, ALP, PTH, 25(OH)D, FGF23 and renal function are tested together to differentiate vitamin D deficiency rickets from XLH.
XLH is confirmed by combining biochemical, imaging and genetic testing.
Biochemical diagnostic criteria: (1) Low serum phosphorus — repeatedly confirmed below the lower limit of normal for age. (2) Low TmP/GFR — demonstrates renal phosphate wasting. (3) Serum calcitriol — inappropriately low or normal relative to the hypophosphatemia. (4) Plasma FGF23 — elevated or inappropriately normal (a normal value in the setting of hypophosphatemia is abnormal). Note that interpretation of FGF23 measurement may vary with the specimen type (EDTA plasma) and assay kit (C-terminal or intact). (5) ALP — elevated (skeletal involvement response). (6) Serum PTH, 25(OH)D, calcium — measured for differential diagnosis.
Genetic diagnosis: Pathogenic variants are identified by direct sequencing (Sanger or NGS) of the PHEX gene. Deletion/duplication analysis (MLPA, etc.) is also included. Even if no gene variant is found, a clinical diagnosis is possible when there is strong clinical evidence.
Differential diagnosis: Differentiation is needed from vitamin D deficiency rickets (distinguished by elevated ALP, low or normal serum phosphorus and low 25(OH)D), ADHR (FGF23 gain-of-function variants), ARHR, tumor-induced osteomalacia (oncogenic osteomalacia; search for a phosphaturic tumor), Fanconi syndrome, vitamin D-dependent rickets types 1 and 2, and others. In adults, it may be confused with osteoporosis, fibromyalgia and spinal stenosis.
Burosumab (Crysvita®): Approved by the FDA and EMA in 2018. A fully human monoclonal antibody (IgG1) against FGF23 that blocks the binding of FGF23 to the FGFR/Klotho complex, restoring renal phosphate reabsorption and increasing calcitriol synthesis. Children (1–17 years): 0.8 mg/kg subcutaneous injection every 2 weeks (minimum 10 mg, maximum 90 mg). Adults: 1 mg/kg subcutaneous injection every 4 weeks (minimum 10 mg, maximum 90 mg). Clinical trials confirmed normalization of serum phosphorus, improvement of rachitic growth plates, improved growth, stabilization of enthesopathy, and improvement in muscle strength and pain. Reported adverse effects include injection site reactions, headache and fever. There is a theoretical risk of ectopic calcification, so caution is needed with excess calcium or phosphate.
Conventional treatment (oral phosphate + active vitamin D): This was the standard treatment before burosumab was introduced and is still used when burosumab is difficult to use. Oral phosphate (1–4 g/day in divided doses) combined with calcitriol (0.5–1.5 μg/day). It improves rickets, but monitoring for adverse effects such as secondary hyperparathyroidism, nephrocalcinosis and hypercalcemia is needed. Burosumab is contraindicated in combination with active vitamin D and phosphate preparations (risk of hypercalcemia and nephrocalcinosis).
Supportive treatment: Orthopedic corrective bone surgery (for severe angular deformities), dental treatment (management of dental abscesses, preventive dental care) and rehabilitation approaches (muscle strengthening, gait rehabilitation) are part of integrated treatment.
XLH is not a life-shortening disease, but without treatment it greatly reduces quality of life throughout life. Even conventional treatment could only partially correct rickets and growth impairment, and various complications persisting into adulthood accumulated, such as enthesopathy, spinal stenosis, nephrocalcinosis and hearing loss. Since the introduction of burosumab, radiographic improvement of growth plate rickets, normalization of renal phosphate handling and accelerated growth have been confirmed in children. In adults, improvements in walking ability, pain and fatigue have also been reported.
However, when childhood treatment is delayed, already established angular lower limb deformities, short stature and hearing loss are not completely corrected by drug treatment alone, and a combined approach including surgery may be needed. Heterozygous females are generally milder than hemizygous males, but their reduced quality of life in adulthood is significant. In the long term, regular follow-up of renal function, hearing and enthesopathy is important.
XLH is a single-gene disorder, and there is no way to prevent its onset itself. However, complications and long-term functional impairment can be minimized with the following strategies.
Genetic counseling: Genetic counseling is recommended for patients with XLH or their families when planning pregnancy. When the father has XLH, it is not transmitted to sons, but daughters are affected 100%. When the mother has XLH, it is transmitted to each son and daughter with a 50% probability.
Prenatal diagnosis: When a PHEX variant has been identified in the family, molecular diagnosis by chorionic villus sampling or amniocentesis is possible.
Early diagnosis and treatment: Treatment is started as early as possible after confirmation to minimize rachitic bone deformities, growth delay and dental complications. Preventive dental care (fluoride application, regular checkups) is important for preventing spontaneous dental abscesses.
Monitoring for complications: Nephrocalcinosis (regular renal ultrasound), secondary hyperparathyroidism (serum PTH follow-up), hearing (regular audiometry) and progression of enthesopathy (imaging follow-up) are followed in a planned manner.